隶属于 president & fellows of harvard college
相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1782
尚未招募
2
100.0%
暂无批准数据
- ASTRO released its first standalone clinical practice guideline on radiation therapy for bladder cancer, published in Practical Radiation Oncology and developed with ASCO, EAU and ESTRO. - The guideline strongly recommends trimodal therapy as an alternative to radical cystectomy for select patients with cT2-4aN0M0 muscle-invasive bladder cancer. - Recommendations also cover adjuvant radiation after cystectomy, dose-fractionation schedules, and palliative or consolidative radiation in metastatic disease. - The task force flagged persistent disparities, including lower receipt of curative-intent treatment among Black patients and reduced access in rural communities.
- Pennsylvania health officials reported four breakthrough measles cases in fully vaccinated residents, the first such cases in the state's 2026 outbreak. - The state's outbreak has reached 676 cases with 124 hospitalizations, making it Pennsylvania's largest measles outbreak in more than 30 years. - MMR vaccination demand surged in August, with providers administering 46,000 doses versus the typical 25,000 per month. - Two measles-associated infant deaths have been reported, though state and federal officials disagree on whether both should be linked to the outbreak.
- A University of Sydney-led analysis of more than 64,000 middle-aged adults found that varied step counts and walking intensities were each linked to lower mortality risk. - Walking fewer than 5,000 steps daily at a brisk pace of about 80 steps per minute produced mortality reductions comparable to 5,000-7,500 slower steps. - A peak 30-minute cadence of roughly 90-100 steps per minute emerged as a potential target, while 7,500-10,000 daily steps tracked with the lowest mortality risk. - Researchers caution the observational design cannot prove causation, and independent experts note step-intensity evidence remains inconsistent across studies.
- The FDA has cleared Quantum BioPharma's Investigational New Drug application for Lucid-MS, allowing a randomized, double-blind, placebo-controlled Phase 2 trial in multiple sclerosis. - Lucid-MS is a patented, first-in-class non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) designed to target demyelination rather than broadly suppress the immune system. - Preclinical models showed Lucid-MS prevented and reversed myelin degradation, and the Phase 2 study will assess safety, tolerability and potential therapeutic effects in patients with MS. - Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on the [18F]3F4AP PET tracer to visualize and measure demyelination.
- Hereditary angioedema treatment goals have shifted from reducing attack frequency to achieving complete freedom from attacks with better quality of life. - Experts identify breakthrough attacks, severe or throat swelling, and life disruptions as signals to reassess preventive therapy in HAE. - Pregnancy and hormonal contraception require early HAE care team involvement, as estrogen is a known trigger and danazol is contraindicated. - Bradykinin-driven swelling in HAE does not respond to antihistamines, corticosteroids, or epinephrine, requiring specialized prescription medications.
- Canada announced the hiring of 64 scholars supported by more than C$500 million ($350 million) over eight years through its Global Impact+ Research Talent Initiative. - Forty-eight of the recruited academics come from US institutions including Harvard, Cornell, and MIT, spanning medicine, engineering, and climate science. - Researchers cited frozen federal grants and concerns over academic freedom under the Trump administration as key factors driving their departure. - The initiative is part of a C$1.7 billion ($1.2 billion) effort to attract world-leading researchers to Canadian universities.
- Harvard-led researchers engineered the marine bacterium Alteromonas macleodii to continuously produce the siderophore petrobactin, decoupling production from environmental iron levels. - The engineered microbes increased olivine dissolution 2.6-fold in small seawater reactors and 3.1-fold in pilot-scale reactors compared with abiotic controls. - Pilot reactors containing over 4 kg of olivine and raw Boston Harbor seawater generated alkalinity equivalent to removing about 0.5 g of atmospheric CO2 per day. - The study demonstrates proof of concept that synthetic biology can accelerate a geological process that normally unfolds over extremely long timescales.
- Harvard and Wyss Institute researchers unveiled AGENTEX, a cell-free platform that builds synthetic proteins using up to 34 custom amino acids instead of nature's 20. - The tool works in test-tube lysate solutions without living cells or genome editing, making protein production faster, safer and scalable, per the Nature study. - A surprise finding overturned decades of tRNA dogma: tRNAs lacking the standard CCA tail can still receive amino acids, enabling orthogonal translation systems. - The team says AGENTEX could accelerate development of novel protein-based therapeutics, while its tSCAN component may aid study of disease-linked tRNA mutations.
- Katrina Maclean, owner of Kat's Creepy Creations in Peabody, Massachusetts, was sentenced to two years in prison for selling body parts stolen from the Harvard Medical School morgue. - Investigators found Maclean purchased stolen body parts before selling and shipping them to other buyers. - Former morgue manager Cedric Lodge received an eight-year sentence, while his wife Denise Lodge was sentenced to one year and one day after pleading guilty. - The case highlights serious breaches in the oversight and security of donated human remains at academic medical institutions.
- Harvard University agreed to pay $53 million to resolve class action lawsuits alleging negligence in its handling of donated human remains at Harvard Medical School's morgue. - Former morgue manager Cedric Lodge was sentenced to eight years in prison for stealing and selling organs, brains, faces, and other body parts from donated cadavers between 2018 and 2022. - The settlement includes a live webinar statement to families affirming Lodge's conduct was "morally reprehensible" and an annual medical student scholarship honoring anatomical donors beginning in 2027-2028. - An initial class action lawsuit estimated between 350 and 400 donated cadavers may have been affected by the misconduct.
